Methods of treating or preventing a complication of sickle cell disease
AssigneeCSL Innovation Pty Ltd
InventorsLisa Margareta LINDQVIST, Andreas GILLE, Paolo ROSSATO, Markus BRECHMANN, John Davis BELCHER, Gregory M. VERCELLOTTI
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for treating or preventing or delaying progression or reducing or inhibiting or hindering development of a complication associated with sickle cell disease in a subject suffering from sickle cell disease, the method comprising administering to the subject a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity.
Claims27
A method for treating or preventing or delaying progression or reducing or inhibiting or hindering development of a complication associated with sickle cell disease in a subject suffering from sickle cell disease, the method comprising administering to the subject a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity.
(canceled)
A method for treating or preventing or delaying progression or reducing or inhibiting or hindering development of a vasculopathy associated with sickle cell disease in a subject suffering from sickle cell disease, the method comprising administering to the subject a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity.
A method of treating or preventing or delaying progression or reducing or inhibiting or hindering development of a vaso-occlusive crisis and/or acute chest syndrome in a subject suffering from sickle cell disease, the method comprising administering to the subject a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating or preventing or delaying progression or reducing or inhibiting or hindering development of a complication associated with sickle cell disease in a subject suffering from sickle cell disease, the method comprising administering to the subject a composition comprising a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.